AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23880258
Drug: 2% CHX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% CHX gel + Ca(OH)2 (G4)
Trial: 23880258
Drug: 2-visit treatment
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2-visit treatment (G3 and G4)
Trial: 23880258
Drug: 1-visit treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-visit treatment (G1 and G2)
Trial: 21972642
Drug: Acupuncture knife
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture knife therapy
Trial: 21972642
Drug: Blocking therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blocking therapy
Trial: 16915770
Drug: Magnetocardiography (MCG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetocardiography (MCG) analysis in CAD patients without MI
Trial: 16915770
Drug: Magnetocardiography (MCG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetocardiography (MCG) analysis in CAD patients with MI
Trial: 16915770
Drug: Magnetocardiography (MCG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetocardiography (MCG) analysis in CAD patients with MI and VT
Trial: 16915770
Drug: Magnetocardiography (MCG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnetocardiography (MCG) analysis in healthy subjects
Trial: 14623061
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg tibolone
Trial: 12207627
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg and 2.5 mg tibolone
Trial: 10509987
Drug: Preoperative IABP
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative IABP therapy starting 2 hours (T2), 12 hours (T12), or 24 hours (T24) before the operation.
Trial: 19635155
Drug: Preoperative IABP
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative IABP therapy
Trial: 2031517
Drug: Ofloxacin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (300 mg, taken twice daily for 7 days)
Trial: 7198936
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy of vincristine, bleomycin, methotrexate, hydrocortisone, and 5-fluorouracil given over 24 hours every 2 to 3 weeks.
Trial: 7198936
Drug: Chemotherapy before
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy before radiation therapy or surgery.
Trial: 7198936
Drug: Primary adjuvant
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary adjuvant chemotherapy without cis-platinum.
Trial: 24049896
Drug: Direct fluorescent
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct fluorescent antibody test
Trial: 22492244
Drug: HPV-16/18 virus-like
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-16/18 virus-like particle vaccine
Trial: 15793272
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral treatment (CBT) combined with asthma education (AE)
Trial: 8912130
Drug: Intravenous ticarcillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ticarcillin and clavulinic acid (Timentin) pre-ERCP (group I)
Trial: 8912130
Drug: Intravenous ticarcillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ticarcillin and clavulinic acid (Timentin) plus 3 days of oral amoxycillin and clavulinic acid (Augmentin) (group II)
Trial: 1811329
Drug: Nizoral cream
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nizoral cream containing ketoconazole
Trial: 7039814
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment C and D (DC containing)
Trial: 576879
Drug: Treatment D
RxNorm normalized name: Earwax Treatment Drops
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment D
Trial: 7039814
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (FU + ME)
Trial: 26467358
Drug: Metoprolol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (1 x 50 mg)
Trial: 26467358
Drug: Carvedilol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (2 x 12.5 mg)
Trial: 22205496
Drug: Budiodarone 400
RxNorm normalized name: Budiodarone
DrugBank: Budiodarone (DB05519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budiodarone 400 mg BID
Trial: 22205496
Drug: Budiodarone 600
RxNorm normalized name: Budiodarone
DrugBank: Budiodarone (DB05519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budiodarone 600 mg BID
Trial: 12122920
Drug: 5-HT3 receptor
RxNorm normalized name: 5-HT3 receptor antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HT3 receptor antagonists
Trial: 17239324
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of a 5-HT3 antagonist, steroids, and aprepitant
Trial: 15598679
Drug: AA/CHO supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AA/CHO supplement
Trial: 12753445
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine 0.5 ml.kg‐1
Trial: 12753445
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine 0.5 ml.kg‐1 with 1 microg x kg‐1 neostigmine
Trial: 25249361
Drug: Placebo ultrasound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ultrasound treatment
Trial: 7389058
Drug: Low-dose cyclophosphamide
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclophosphamide (CTX) 100 mg/day continuously
Trial: 7389058
Drug: Adriamycin (ADM)
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adriamycin (ADM) 50 mg/m2 IV every 4 weeks plus CTX 100 mg/day
Trial: 27457790
Drug: Polysaccharide-resin-honey based
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysaccharide-resin-honey based cough syrup
Trial: 27457790
Drug: Carbocysteine syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbocysteine syrup
Trial: 16478844
Drug: Interdisciplinary intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interdisciplinary intervention group receiving medical care, asthma education, and problem-solving therapy (n = 89)
Trial: 31389718
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy
Trial: 11096044
Drug: Combined conventional
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined conventional treatment and sorbent suspension dialysis (6-hour treatment)
Trial: 9375591
Drug: Clomipramine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine treatment starting at 10 mg/day, gradually increased to a mean dose of 97 mg/day
Trial: 8262686
Drug: Pirenzepine and
RxNorm normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine and H2-receptor antagonists (cimetidine, ranitidine)
Trial: 26417001
Drug: Adjuvant hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormone therapy (AHT) for 5 years
Trial: 9278212
Drug: Theophylline (non-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (non-specific adenosine antagonist)
Trial: 9278212
Drug: Dipyridamole (adenosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (adenosine reuptake inhibitor)
Trial: 8020521
Drug: iomeprol 200
RxNorm normalized name: IOMEPROL
DrugBank: Iomeprol (DB11705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iomeprol 200 mgI/ml
Trial: 8020521
Drug: iopamidol 200
RxNorm normalized name: iopamidol 200 mg iodine/mL (41 %) INJECTION VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iopamidol 200 mgI/ml
Trial: 2532444
Drug: Droperidol 0.010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.010 mg/kg
Trial: 2532444
Drug: Droperidol 0.005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.005 mg/kg
Trial: 810268
Drug: Intranasal betamethasone
RxNorm normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal betamethasone valerate
Trial: 31724354
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (conjugated estrogens and medroxyprogesterone acetate)
Trial: 28323173
Drug: Cardiac Resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac Resynchronization Therapy (CRT) + Optimal Pharmacological Therapy (OPT)
Trial: 28323173
Drug: Optimal Pharmacological
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal Pharmacological Therapy (OPT)
Trial: 12594415
Drug: Combination headgear
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination headgear
Trial: 12594415
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment until permanent dentition
Trial: 10376260
Drug: 0.2 mg/cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/cc MMC
Trial: 10376260
Drug: 0.4 mg/cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/cc MMC
Trial: 3460737
Drug: Ofloxacin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (300 mg) with breakfast
Trial: 3460737
Drug: Ofloxacin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (300 mg) fasting
Trial: 27651908
Drug: Pulmonary artery
RxNorm normalized name: Pulmonary artery blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary artery perfusion with histidine‐tryptophan‐ketoglutarate (HTK) solution (n=29)
Trial: 15933485
Drug: Fluoxetine/Paroxetine (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine/Paroxetine (n = 298)
Trial: 3108794
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of perioperative antibiotic prophylaxis with cefoperazone sodium
Trial: 18245800
Drug: Various experimental
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various experimental treatments (specific treatments not detailed)
Trial: 10100144
Drug: Vinorelbine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine 25 mg/m2 on days 1 and 8; Gemcitabine 1000 mg/m2 on days 1 and 8; Cisplatin 75 mg/m2 on day 8, repeated every 21 days for a maximum of six cycles.
Trial: 10100144
Drug: Vinorelbine, gemcitabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine, gemcitabine, and cisplatin combination therapy
Trial: 8915032
Drug: Linomide (8-9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linomide (8-9 mg/kg/day) in drinking water
Trial: 8915032
Drug: Linomide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linomide (10 mg/kg) i.p. for 3 days
Trial: 8915032
Drug: Linomide (8-9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linomide (8-9 mg/kg/day) with rhIL-1beta (4.0 microg/kg) i.p. daily for 5 days
Trial: 8915032
Drug: rhIL-1beta (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL-1beta (4.0 microg/kg) i.p. daily for 5 days
Trial: 1745715
Drug: Lorazepam (0.0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (0.0, 0.6, 0.13, 0.25, and 0.5 mg; total cumulative dose: 0.94 mg)
Trial: 1745715
Drug: Lorazepam (0.94
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (0.94 mg)
Trial: 30806017
Drug: Lidocaine 5%
RxNorm normalized name: LIDOCAINE 5% OINT
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 5% patch
Trial: 9506336
Drug: Cilostazol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol (200 mg/day)
Trial: 8067708
Drug: ACNU or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACNU or BCNU (adjuvant chemotherapy)
Trial: 30053572
Drug: Antidepressant consumption
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant consumption
Trial: 23611212
Drug: Dasatinib 100
RxNorm normalized name: dasatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 100 mg orally daily
Trial: 23611212
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg orally daily
Trial: 20800376
Drug: Total body
RxNorm normalized name: Total Body Massager Item
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total body irradiation (TBI) with 800 cGy delivered in two 200‐cGy fractions twice a day before CD34(+) selected autologous hematopoietic stem cell transplantation.
Trial: 17146008
Drug: C‐ECT (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C‐ECT (10 treatments)
Trial: 14762617
Drug: Guidelines for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guidelines for epilepsy treatment based on the opinion of Brazilian experts
Trial: 10750067
Drug: Daily iron/folate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily iron/folate supplementation
Trial: 10750067
Drug: Once-weekly iron/folate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly iron/folate supplementation
Trial: 31274545
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (ITM) with 100μg of morphine
Trial: 20605441
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 10 mg
Trial: 20605441
Drug: 1% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% ropivacaine 20 mg
Trial: 20605441
Drug: 0.5% levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% levobupivacaine 10 mg
Trial: 17921382
Drug: Iodine supplementation
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine supplementation (191 mg I as oral iodized oil)
Trial: 17921382
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of iodine and vitamin A supplementation
Trial: 8696714
Drug: MIP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIP regimen (mitomycin C 6 mg/m2 on day 1, ifosfamide 1500 mg/m2 on days 1-3, cisplatin 30 mg/m2 on days 1-3 every 4 weeks)
Trial: 1948213
Drug: Cephalexin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin (500 mg bid or qid)
Trial: 1948213
Drug: Ofloxacin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (300 or 400 mg bid)
Trial: 30264137
Drug: Digital Cognitive
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital Cognitive Behavioral Therapy (dCBT)
Trial: 26545405
Drug: Doxorubicin/cyclophosphamide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin/cyclophosphamide treatment
Trial: 17643586
Drug: High-dose tirofiban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose tirofiban + clopidogrel 600-mg loading dose
Trial: 17643586
Drug: Eptifibatide +
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide + clopidogrel 600-mg loading dose
Trial: 9809692
Drug: Alcohol restriction
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol restriction (maximum of 15 mL/day)
Trial: 7631286
Drug: Calcium antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonist + beta-blocking agent
Trial: 2575833
Drug: 0.8 mg
RxNorm normalized name: biotin 0.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg pindolol
Trial: 2575833
Drug: 1.6 mg
RxNorm normalized name: menthol 1.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg pindolol
Trial: 25633573
Drug: Paricalcitol 1
RxNorm normalized name: PARICALCITOL 1MCG CAP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paricalcitol 1 mcg administered orally once daily for three months
Trial: 25633573
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally once daily for three months
Trial: 22130240
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg intravenous bolus
Trial: 22130240
Drug: 0.75 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg/kg intravenous bolus
Trial: 22130240
Drug: 1.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.05 mg/kg intravenous bolus
Trial: 22130240
Drug: 0.75 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg per hour infusion for 4 h
Trial: 15253685
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) IFNbeta-1a (Avonex)
Trial: 15253685
Drug: Subcutaneous (s.c.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c.) IFNbeta-1a (Rebif)
Trial: 11693798
Drug: Cisplatin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (30 mg/m2 daily for 3 days) + Vindesine (2.5 mg/m2 only day 1) + Dacarbazine (DTIC) (250 mg/m2 daily for 3 consecutive days) + Interferon-alpha (3 MIU i.m. 3x/wk continuously)
Trial: 11693798
Drug: Dacarbazine (DTIC)
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine (DTIC) (800 mg/m2 day 1) + Interferon-alpha (3 MIU i.m. 3x/wk continuously)
Trial: 8204227
Drug: 0.8 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mg/kg of i.v. ketorolac
Trial: 8204227
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional analgesic (morphine only group)
Trial: 3311438
Drug: One tablet
RxNorm normalized name: Hydone Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of Fansimef (250 mg mefloquine, 500 mg sulfadoxine, 25 mg pyrimethamine)
Trial: 3311438
Drug: Two tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of Fansimef
Trial: 3311438
Drug: Three tablets
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three tablets of Fansimef
Trial: 23811853
Drug: Pioglitazone (PIO)
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone (PIO) 15 mg/day
Trial: 21457428
Drug: Canagliflozin (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin (10, 30, 100, 200, 400, 600 or 800 mg q.d. or 400 mg b.i.d.)
Trial: 21457428
Drug: Canagliflozin (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin (doses >200 mg before breakfast)
Trial: 17057562
Drug: Dextromethorphan (DM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DM) 40 mg + Ketorolac 60 mg
Trial: 17057562
Drug: Dextromethorphan (DM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DM) 40 mg
Trial: 8707552
Drug: Ketorolac 60
RxNorm normalized name: ketorolac 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 60 mg
Trial: 17057562
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (C): IM chorpheniramine 20 mg + IV normal saline
Trial: 15064540
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by interval debulking surgery
Trial: 9400786
Drug: MSL-109, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSL-109, 60 mg intravenously every 2 weeks
Trial: 9400786
Drug: MSL-109, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSL-109, 60 mg intravenously every 2 weeks (relapsed retinitis)
Trial: 9400786
Drug: MSL-109, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSL-109, 60 mg intravenously every 2 weeks (newly diagnosed retinitis)
Trial: 8265305
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of human serum immunoglobulin (300 mg/kg body weight)
Trial: 28255655
Drug: 2.5 mL
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL of 1% HA (H-HA)
Trial: 28255655
Drug: 0.8 mL
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8 mL of 1% HA (L-HA)
Trial: 28255655
Drug: 2.5 mL
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL of 0.01% HA (control group)
Trial: 25171889
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy for primary care (PST-PC)